As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
BUSINESS
Novartis Offers Free Access Program for Zolgensma Diagnostic
Novartis Pharma on May 8 started a free access program for “MEBCDX AAV9,” the companion diagnostic for its spinal muscular atrophy (SMA) gene therapy Zolgensma, in order to fill a void before the test kit’s reimbursement listing and deliver the…
To read the full story
Related Article
- Zolgensma Hits Japan Market with Stringent Conditions Attached
May 21, 2020
- Chuikyo Members Frown on Zolgensma’s Sakigake Premium; Topic Up for 2022 Pricing Debate
May 14, 2020
- Japan Regulators Upped Zolgensma Price after Novartis Complaints: Chuikyo Paper
May 13, 2020
- Zolgensma to Get Japan’s Highest List Price 167 Million Yen, but Peak Sales Put at Just 4 Billion Yen
May 12, 2020
- SMA Patient Group Presses MHLW to Hasten Zolgensma Listing
April 17, 2020
- (Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually
March 19, 2020
BUSINESS
- Despite Spike in Flu Cases, Vaccine Shipments Down in FY2024: Wholesalers
January 28, 2025
- Nippon Shinyaku Bags US License Option for AB2 Bio’s Tadekinig Alfa
January 28, 2025
- Leqembi’s Monthly IV Maintenance Dosing Approved in US
January 28, 2025
- Astellas Slashes Full-Year Profit Forecasts on Impairment Loss of Izervay and More
January 27, 2025
- Rakuten Medical Launches Global PIII Trial of Photoimmunotherapy/Keytruda Combo
January 27, 2025
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…